《Pharmacophore modelling of 2-chlorobenzimidazole and its specific docking to the active site c-Met Kinase: A search for potent c-Met Kinase inhibitor》 was published in Pharmaceutical and Chemical Journal in 2020. These research results belong to Otuokere, I. E.; Igwe, K. K.; Amaku, J. F.; Ikpeazu, O. V.. SDS of cas: 4857-06-1 The article mentions the following:
In this paper, we demonstrate how pharmacophore modeling was used to design the analogs of 2-chlorobenzimidazole and the application of mol. docking studies in the evaluation of the ligand affinity for the target. The lead mol. (1-benzyl-2-chloro-1H-benzimidazole) had the highest docking score of -8.0 kcal/mol and was observed to interact with 17 amino acids within the pocket of c-Met Kinase (ALA159, VAL39, TYR32, MET144, ASN142, ARG141, ALA154, ASP155, ALA49, LYS51, LEU90, TYR92, MET93, GLY32, ILE, ASP97 and GLY96). Meanwhile, the ADME characteristics of 1-benzyl-2-chloro-1H-benzimidazole showed approving properties of the lead mol. Hence, we recommend 1-benzyl-2-chloro-1H-benzimidazoleas promising candidates with high potential to inhibit c-Met Kinase.2-Chloro-1H-benzo[d]imidazole(cas: 4857-06-1SDS of cas: 4857-06-1) was used in this study.
2-Chloro-1H-benzo[d]imidazole(cas: 4857-06-1) binds to monoclonal antibodies, inhibiting their binding to their corresponding antigens. This activity may be due to its ability to bind covalently with amino groups on proteins and other molecules.SDS of cas: 4857-06-1
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem